Skip to main content

Immunotherapy Trials Show Promise Against Stomach and Esophagus Cancers

Results from two Phase I studies demonstrate that immune checkpoint inhibitors may be beneficial for patients with certain cancers of the esophagus and stomach. Roughly one-third of patients in the studies had their disease controlled by nivolumab or pembrolizumab, according to presentations at the 2016 Gastrointestinal Cancers Symposium (abstracts 6 and 7).

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino